- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant treatment of breast cancer
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 23, Issue suppl 10, Pages x231-x236
Publisher
Oxford University Press (OUP)
Online
2012-09-17
DOI
10.1093/annonc/mds324
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC)
- (2017) C. J. Poole et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer
- (2012) Antonio Llombart-Cussac et al. Clinical & Translational Oncology
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial
- (2011) Sirwan Hadad et al. BREAST CANCER RESEARCH AND TREATMENT
- Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients
- (2011) Xiangnan Kong et al. EUROPEAN JOURNAL OF CANCER
- A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
- (2011) Christos Hatzis JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
- (2011) Matthew J. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer-a systematic review and meta-analysis
- (2011) Veronique K.M. Tan et al. JOURNAL OF SURGICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results
- (2011) B. K. Arun et al. ONCOLOGIST
- Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
- (2010) Jens Huober et al. BREAST CANCER RESEARCH AND TREATMENT
- The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study
- (2010) E. J. Macaskill et al. BREAST CANCER RESEARCH AND TREATMENT
- Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
- (2010) W. Fraser Symmans et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer
- (2008) Jae Hong Seo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started